Candel Therapeutics, Inc. (NASDAQ: CADL) is a Healthcare company (Biotechnology) with a market capitalization of $424M. The Maz Rating grades it against the other companies in its sector.
Candel Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.40, Candel Therapeutics, Inc. trades at 3.2x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -88.6%, return on invested capital of -44.4% and a free cash flow yield of -16.7%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 7.57. Over the past 52 weeks the share price ranged from $4.35 to $14.00, with a beta of -0.47.
Candel Therapeutics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Candel Therapeutics, Inc. (CADL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.20% / 30% · (Cash+Inv) / Mkt Cap (36m) 26.5% / 30% · Interest income / Revenue 181600000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.20% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 26.5% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 181600000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.20% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 26.5% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 181600000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 7.11% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.4% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 181600000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.74% / 33.33% · (Cash+ST Inv) / Total Assets 96.2% / 33.33% · (Cash+Recv) / Total Assets 96.2% / 33.33% · Interest income / Revenue 181600000.0% / 5% | Fail |
No. As of September 2026, Candel Therapeutics, Inc. (CADL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Candel Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 181600000.0% of each dividend: Candel Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.